

Our Ref: 095/2020  
March 2020

## Re: Your request made under the Freedom of Information Act 2000

---

- 1) How many patients have been diagnosed over the last 6 months with epithelial ovarian, fallopian tube or primary peritoneal cancer? If none, do you refer ovarian cancer patients to another trust, if so which one?

**There were 24 patients diagnosed between 01/10/2019 and 31/03/2020**

- 2) Of the ovarian patients, how many have been tested for BRCA mutation?

**This cannot be answered as we do not have a specific code to show a BRCA mutation.**

*If unknown please state unknown and move to Question 4*

- 3) Of the ovarian patient BRCA mutation tests how many tested positive?

- 4) Of the ovarian patients diagnosed over the last 6 months, how many have been treated with the below:

Paclitaxel in combination with a platinum-based compound

Platinum-based therapy alone (cisplatin or carboplatin)

Bevacizumab in combination with paclitaxel and carboplatin

Olaparib

Niraparib

Rucaparib

Pegylated liposomal doxorubicin hydrochloride (PLDH) as monotherapy or in combination with a platinum-based compound

**This cannot be answered. While these patients may receive part of their treatment at DRI they are technically Sheffield Teaching Hospital patients and the treatment is prescribed on the STH Chemo-care system.**

- 5) Of those who were positive for a BRCA mutation, how many received Olaparib for 1st line maintenance?

**This cannot be answered as explained above.**

- 6) Of those who were positive for a BRCA mutation, how many received Bevacizumab in combination with paclitaxel and carboplatin for 1st line maintenance?

**This cannot be answered as explained above.**